Cardiac toxicity represents one of the leading causes of drug failure along different stages of
drug development. Multiple very successful pharmaceuticals had to be pulled from the …

Abstract Introduction The Comprehensive in vitro Proarrhythmia Assay (CiPA) is intended to
address the misidentification of drug-associated torsade de pointes risk based solely on …

Abstract Introduction The Comprehensive in vitro Proarrhythmia Assay (C i PA) is a
nonclinical Safety Pharmacology paradigm for discovering electrophysiological mechanisms …

To save time and cost for drug discovery, a paradigm shift in cardiotoxicity testing is
required. We introduce a novel screening system for drug-induced arrhythmogenic risk that …

Late sodium current (late INa) inhibition has been proposed to suppress the incidence of
arrhythmias generated by pathological states or induced by drugs. However, the role of late …

Abstract Introduction The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative
proposes a three-step approach to evaluate proarrhythmogenic liability of drug candidates …

Chinese materia medica (CMM) has been applied for the prevention and treatment of
diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure …

The risk of fatal arrhythmias is the major concern for using chloroquine (CQ) or
hydroxychloroquine (HCQ) to treat coronavirus disease 2019 (COVID‐19), but the reported …

Introduction For reliable identification of cardiac safety risk, compounds should be screened
for activity on cardiac ion channels in addition to hERG, including Na V 1.5 and Ca V 1.2. We …

Cellular asymmetry is an important element of efficiency in the compartmentalization of
intracellular chemical reactions that ensure efficient tissue function. Improving the current 3D …